---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061579"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:23:02.247176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan

## Summary
- Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.
- Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.
- Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.
- End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.
- EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization.

## SEC filing metadata
- accession: 0001104659-24-061579
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/0001104659-24-061579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/tm2414469d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061579
- JSON: https://secwatch.observer/filing/0001104659-24-061579.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061579.txt

## Key facts
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $4.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $4.4 million or $0.28 per diluted share
  - EPS: $0.28 per diluted share
  - Result: reported results
  source text: The Company reported a net loss of $4.4 million or $0.28 per diluted share for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/0001104659-24-061579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.